Amedisys shareholders approve $3.3B UnitedHealth union

12 Sep 2023
www.mobihealthnews.com
Acquisition
Amedisys shareholders approve $3.3B UnitedHealth union
Preview
Source: mobihealthnews
Photo: MoMo Productions/Getty Images
Shareholders of healthcare-at-home specialist Amedisys voted in favor of the roughly $3.3 billion pending acquisition by Optum, a subsidiary of UnitedHealth Group, according to a Securities and Exchange Commission filing.
The shareholders approved the adoption of the merger agreement, as well as compensation to the company's executive officers in connection with the merger.
Still, the deal continues to be under review by the Department of Justice.
Amedisys filed notifications of the merger with the Federal Trade Commission and Antitrust Division of the Department of Justice in July, and in an SEC filing last month said it received a request for additional information from the DOJ, extending the HSR Act waiting period until the parties have fulfilled the DOJ's demands.
Though shareholders have approved the deal, its finalization is subject to approval from certain state regulatory and government authorities.
THE LARGER TREND
In June, UnitedHealth Group announced its plans to purchase the Louisiana-based home healthcare provider in an all-cash deal, beating out Option Care Health.
According to a May SEC filing, Option Care Health entered into an Agreement and Plan of Merger with the home health company in an all-stock offer, but just one month later entered into a termination agreement that included a termination fee of $106 million payable within 24 hours of the execution of the agreement.
In February, United Healthcare finalized its acquisition of another home health company, LHC Group, in a $5.4 billion deal, further expanding its reach in the home healthcare market.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.